Trial site
Saint Petersburg
- 11running trials
- 21closed trials
The trials here
What the 32 trials at this site are about, from their registry records.
- Conditions
- Chronic myeloid leukaemia6 trials
- Childhood cancers3 trials
- Lung cancer3 trials
- Multiple sclerosis3 trials
- Chronic spontaneous urticaria2 trials
- Coronary artery disease2 trials
- Hidradenitis suppurativa2 trials
- IgA nephropathy2 trials
- Metastatic breast cancer2 trials
- Myeloproliferative neoplasms2 trials
- Stroke2 trials
- Acute lymphoblastic leukaemia1 trial
- and 13 more
- Phase
- Phase 320 trials
- Phase 27 trials
- Phase 43 trials
- Status
- Completed18 trials
- Active, not recruiting10 trials
- Terminated3 trials
- Recruiting1 trial
- Lead sponsor
- Novartis Pharmaceuticals32 trials
Running trials
Active, not recruiting
Active, not recruiting
Active, not recruiting
Active, not recruiting
Recruiting
Active, not recruiting
Recruiting
Active, not recruiting
Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS
Active, not recruiting
Active, not recruiting
Active, not recruiting
Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
- Acute lymphoblastic leukaemia1 recruiting
- Childhood cancers1 recruiting
- Chronic myeloid leukaemia1 recruiting
- Myeloproliferative neoplasms1 recruiting
Closed trials
Completed
Completed
Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients
Completed
Study of Safety and Tolerability of CFZ533 in Patients With Sjögren's Syndrome
Completed
Terminated
Terminated
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Study the Efficacy and Safety of VAY736 and CFZ533 in SLE Patients
Completed
Completed
Completed
Terminated
Completed
Completed
Completed
Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)
Completed
Site data: ClinicalTrials.govUpdated 17 Nov 2026